Variant: rs121913465 

    present in Gene: EGFR;EGFR-AS1
    present in Chromosome: 7
    Position on Chromosome: 55181312
    Alleles of this Variant: G/T

rs121913465 in EGFR;EGFR-AS1 gene and Esophageal carcinoma PMID 16707764 2006 Gefitinib-sensitizing mutations in esophageal carcinoma.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121913465 in EGFR;EGFR-AS1 gene and Non-Small Cell Lung Carcinoma PMID 15623594 2004 High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

PMID 19536777 2010 Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

PMID 16205628 2006 Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.

PMID 16863509 2006 EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 19147750 2009 Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

PMID 17653080 2008 EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.

PMID 20522446 2010 We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib.

rs121913465 in EGFR;EGFR-AS1 gene and Squamous cell carcinoma of lung PMID 22753918 2012 Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PMID 23102728 2013 MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.